M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia (scientific article published on November 2015)

CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury

Q73503153

A subpopulation of neuronal M4 muscarinic acetylcholine receptors plays a critical role in modulating dopamine-dependent behaviors

Q24645678

Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats

Q24652668

Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice

Q24678512

The NMDA receptor is coupled to the ERK pathway by a direct interaction between NR2B and RasGRF1.

Q27863780

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

Q28376193

A critical time window for dopamine actions on the structural plasticity of dendritic spines

Q28397378

Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies

Q28580861

Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease

Q29144918

The role of the basal ganglia in habit formation

Q29619829

Dichotomous dopaminergic control of striatal synaptic plasticity

Q30493521

Competitive regulation of synaptic Ca2+ influx by D2 dopamine and A2A adenosine receptors

Q30495714

RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits

Q30504550

Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia

Q30650489

Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia

Q33280726

An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission

Q33308569

Cyclic AMP and afferent activity govern bidirectional synaptic plasticity in striatopallidal neurons

Q33575226

Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.

Q33817654

From reinforcement learning models to psychiatric and neurological disorders

Q34161002

Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems

Q34176570

M4 mAChR-mediated modulation of glutamatergic transmission at corticostriatal synapses

Q34404258

Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons.

Q34521936

Remote control of neuronal signaling

Q34858531

L-DOPA-Induced Dyskinesia and Abnormal Signaling in Striatal Medium Spiny Neurons: Focus on Dopamine D1 Receptor-Mediated Transmission

Q35424424

Neural mechanisms of reward-related motor learning

Q35602987

Mitogen-activated protein kinases in synaptic plasticity and memory.

Q35803116

Modulation of striatal projection systems by dopamine

Q36367283

Dopamine-mediated regulation of corticostriatal synaptic plasticity.

Q36762821

Molecular mechanisms of L-DOPA-induced dyskinesia

Q37247578

Cholinergic modulation of multivesicular release regulates striatal synaptic potency and integration

Q37323686

Phosphorylation of Ser1166 on GluN2B by PKA is critical to synaptic NMDA receptor function and Ca2+ signaling in spines

Q37479508

Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.

Q37597274

Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum

Q37680104

Neuromodulatory control of striatal plasticity and behavior.

Q37844744

A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale

Q38043416

Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors

Q38890700

Endocannabinoid signaling mediates psychomotor activation by adenosine A2A antagonists.

Q39353443

Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment

Q39398723

Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models

Q41584434

Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice

Q42168324

Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.

Q42459246

Input- and cell-type-specific endocannabinoid-dependent LTD in the striatum.

Q42470816

Distinct coincidence detectors govern the corticostriatal spike timing-dependent plasticity.

Q42473820

Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function

Q42491215

A Ca(2+) threshold for induction of spike-timing-dependent depression in the mouse striatum.

Q42494007

Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models

Q42508054

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

Q44050418

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

Q44383212

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

Q44436562

Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons

Q45299250

Muscarinic inhibition of hippocampal and striatal adenylyl cyclase is mainly due to the M(4) receptor.

Q46134759

L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

Q46136644

Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity.

Q46717148

Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons.

Q46973834

Reversal of cocaine-evoked synaptic potentiation resets drug-induced adaptive behaviour

Q48204993

Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes

Q48433708

Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons

Q48441601

D1/D5 dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism.

Q48514262

RGS4 inhibits signaling by group I metabotropic glutamate receptors.

Q48539239

SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance

Q48720514

Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity

Q59065408

The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease

Q60715991

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

dyskinesia

Q629444

striatum

Q1319792

P304

page(s)

762-773

P577

publication date

2015-11-01

P1433

published in

Neuron

Q3338676

P1476

title

M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

P478

volume

Reverse relations

cites work (P2860)

Q47378768	A Feedforward Inhibitory Circuit Mediated by CB1-Expressing Fast-Spiking Interneurons in the Nucleus Accumbens
Q49342323	A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia.
Q89167851	Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia
Q90205448	An Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency for Regulators of G-protein Signaling Proteins 4, 8, and 19
Q41159357	Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release
Q99619162	Basal Ganglia-A Motion Perspective
Q49361175	Basal ganglia mechanisms in action selection, plasticity, and dystonia.
Q48631361	Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.
Q46447901	Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs
Q47581410	Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.
Q50993859	Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.
Q37507773	Cholinergic Interneurons Amplify Corticostriatal Synaptic Responses in the Q175 Model of Huntington's Disease.
Q52740407	Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.
Q88803206	Cholinergic modulation of striatal microcircuits
Q64251973	Delayed Spine Pruning of Direct Pathway Spiny Projection Neurons in a Mouse Model of Parkinson's Disease
Q49821000	Differential Protein Dynamics of Regulators of G-protein Signaling: Role in Specificity of Small-molecule Inhibitors.
Q38436762	Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition
Q38437959	Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core
Q47644788	Discovery of a novel 2,4-dimethylquinoline-6-carboxamide M4 positive allosteric modulator (PAM) chemotype via scaffold hopping
Q47864774	Discovery of a novel, CNS penetrant M4 PAM chemotype based on a 6-fluoro-4-(piperidin-1-yl)quinoline-3-carbonitrile core
Q89584480	Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease
Q47563473	Effects of muscarinic M1 and M4 acetylcholine receptor stimulation on extinction and reinstatement of cocaine seeking in male mice, independent of extinction learning.
Q60141509	Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism
Q54981672	Inhibition of basal and amphetamine-stimulated extracellular signal-regulated kinase (ERK) phosphorylation in the rat forebrain by muscarinic acetylcholine M4 receptors.
Q90304563	Interplay of cysteine exposure and global protein dynamics in small-molecule recognition by a regulator of G-protein signaling protein
Q42498429	Involvement of Striatal Cholinergic Interneurons and M1 and M4 Muscarinic Receptors in Motor Symptoms of Parkinson's Disease
Q52655473	Kainate Receptors Inhibit Glutamate Release Via Mobilization of Endocannabinoids in Striatal Direct Pathway Spiny Projection Neurons.
Q48113066	Levodopa treatment and dendritic spine pathology
Q37516434	Maladaptive Synaptic Plasticity in L-DOPA-Induced Dyskinesia
Q48177380	Metformin Inhibits the Development of L-DOPA-Induced Dyskinesia in a Murine Model of Parkinson's Disease.
Q38820286	Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology
Q64779296	Optogenetic Stimulation of the M2 Cortex Reverts Motor Dysfunction in a Mouse Model of Parkinson's Disease
Q64911660	Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
Q54936284	Pauses in cholinergic interneuron firing exert an inhibitory control on striatal output in vivo.
Q43076051	Physiological roles of CNS muscarinic receptors gained from knockout mice.
Q39067400	Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders
Q91900172	RGS4 Maintains Chronic Pain Symptoms in Rodent Models
Q64901815	Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.
Q47909580	Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Q39190510	Roles of centromedian parafascicular nuclei of thalamus and cholinergic interneurons in the dorsal striatum in associative learning of environmental events
Q64759887	Roles of the M4 acetylcholine receptor in the basal ganglia and the treatment of movement disorders
Q33559375	Spine Enlargement of Pyramidal Tract-Type Neurons in the Motor Cortex of a Rat Model of Levodopa-Induced Dyskinesia
Q64086843	Spiny Projection Neuron Dynamics in Toxin and Transgenic Models of Parkinson's Disease
Q42330741	Spontaneous Synaptic Activation of Muscarinic Receptors by Striatal Cholinergic Neuron Firing
Q26768220	Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?
Q89326911	Striatal Rgs4 regulates feeding and susceptibility to diet-induced obesity
Q46145089	Striatal cholinergic interneurons and D2 receptor-expressing GABAergic medium spiny neurons regulate tardive dyskinesia
Q39414543	Striatal cholinergic interneurons and Parkinson's disease.
Q48138673	Striatal synapses, circuits, and Parkinson's disease
Q89948582	Synaptic and cellular plasticity in Parkinson's disease
Q39381131	Synaptic functions of endocannabinoid signaling in health and disease
Q52371217	Synaptic plasticity and levodopa-induced dyskinesia: electrophysiological and structural abnormalities.
Q90053610	Targeting the cholinergic system in Parkinson's disease
Q89701501	The Dopamine D5 receptor contributes to activation of cholinergic interneurons during L-DOPA induced dyskinesia
Q52680310	The striatal cholinergic system in L-dopa-induced dyskinesias.
Q58090420	Thinking Outside the Box (and Arrow): Current Themes in Striatal Dysfunction in Movement Disorders
Q93054105	Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease
Q88671319	What does dopamine mean?